Esperion Therapeutics Inc (ESPR), Intercept Pharmaceuticals Inc (ICPT): Visium and OrbiMed’s Recent Activity in Biotech
Stocks in the biotechnology industry have been very active as of late, with companies' shares registering significant gains.
Posts Tagged ‘Hedge Fund:254’
Healthcare Hedge Fund Orbimed’s Top Picks and New Move
According to a Schedule 13D form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals...
Sientra Inc (SIEN), TESARO Inc (TSRO) and Clovis Oncology Inc (CLVS): Orbimed’s Top New Picks
Samuel Islay's Orbimed Advisors has revealed its equity portfolio as of end of 2014, in a recent filing with the Securities and Exchange Commission.
Ascendis Pharma A/S (ASND): Orbimed Advisors Takes Activist Stake in Newly Public Company
Samuel Isaly’s Orbimed Advisors has taken an activist stake in the recently listed Ascendis Pharma A/S (NASDAQ:ASND), an early-stage drug company working on a novel method of...
Sientra Inc (SIEN): Orbimed Discloses Major Stake in Newly Public Company
Samuel Isaly's healthcare-focused fund Orbimed Advisors has disclosed a new position in Sientra Inc (NASDAQ:SIEN), a company that just has gone public.
Altisource Asset Management Corp (AAMC), Affimed Therapeutics BV (AFMD): Orbimed Advisors and Luxor Capital Group Are Bullish on These Companies
Altisource Asset Management Corp (NYSEMKT:AAMC) and Affimed Therapeutics BV (NASDAQ:AFMD) felt hedge funds’ bullishness lately.
Relypsa Inc (RLYP): Orbimed Advisors Trims Its Exposure to the Company
As a new filing with the Securities and Exchange Commission showed today, Samuel Isaly's Orbimed Advisors have trimmed its exposure to Relypsa Inc (NASDAQ:RLYP).
Intercept Pharmaceuticals Inc. (ICPT), Bristol-Myers Squibb Co (BMY), Biogen Idec Inc (BIIB): Orbimed Advisors Top Stocks in Q2
Orbimed Advisors, led by Samuel Isaly, recently published its 13F filing with the U.S. Securities and Exchange Commission.
Orbimed Advisors Further Cuts Exposure To Intercept Pharmaceuticals Inc. (ICPT)
Orbimed Advisors, led by Samuel Isaly, has disclosed cutting its position in Intercept Pharmaceuticals Inc. (NASDAQ:ICPT).
Loxo Oncology Inc (LOXO): Deerfield Management Discloses 13.65% Activist Stake
Samuel Isaly's Orbimed Advisors has disclosed holding a stake in Loxo Oncology Inc (NASDAQ:LOXO).
Orbimed Advisors Cuts Stake In Intercept Pharmaceuticals Inc (ICPT)
Orbimed Advisors is limiting exposure to Intercept Pharmaceuticals Inc (NASDAQ:ICPT), after selling approximately 81,305 shares in one transaction at $320 a piece, according...
Samuel Isaly Says He Is Fond of Regeneron Pharmaceuticals Inc (REGN) & InterMune Inc (ITMN)
Samuel Isaly's Orbimed Advisors is one of the largest hedge funds focused almost entirely on the healthcare sector. In a recent intervention on CNBC, Mr.
Samuel Isaly, Orbimed Advisors Disclose Position in Post-IPO Relypsa
Sam Isaly’s Orbimed Advisors disclosed its position in Relypsa Inc (NASDAQ:RLYP), a company that recently conducted its IPO.
Sam Isaly, Orbimed Now Hold 53.3% of Response Biomedical
Sam Isaly's Orbimed Advisors focuses on healthcare investments, and it has now disclosed a change to its holdings of Response Biomedical Corp.
Samuel Isaly, Orbimed Advisors Lower Position in NxStage Medical
Samuel Isaly's hedge fund, Orbimed Advisors, decreased its stake in NxStage Medical, Inc. (NASDAQ:NXTM) to around 2.89 million shares, from 3.14 million held earlier.
Orbimed Follows Baker Bros and Buys Some Mirati Therapeutics Shares
Orbimed Advisors, a fund focused on the healthcare sector, led by Samuel Isaly, disclosed minutes ago purchasing 125,000 shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX).
Samuel Isaly’s Orbimed Advisors Sells Some Intercept Pharmaceuticals Stock at $62.50/Share
Orbimed Advisors, Intercept Pharmaceuticals: Samuel Isaly and his hedge fund, Orbimed Advisors, is focused on healthcare stocks.
Orbimed Downgrades its Position in Intercept Pharmaceuticals
Orbimed Advisors, Intercept Pharmaceuticals: In a recent SEC filing, Samuel Isaly and his hedge fund, Orbimed Advisors, reported decreasing their holding in Intercept Pharmaceuticals...
Should You Buy Regeneron Pharmaceuticals Inc (REGN)?
If you were to ask many investors, hedge funds are viewed as delayed, outdated investment vehicles of an era lost to time.
Hedge Funds Are Crazy About BioMarin Pharmaceutical Inc. (BMRN)
In the financial world, there are dozens of gauges shareholders can use to analyze stocks. Two of the most under-the-radar are hedge fund and insider trading sentiment.
Hedge Funds Are Buying Amgen, Inc. (AMGN)
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
This Metric Says You Are Smart to Buy Merck & Co., Inc. (MRK)
Now, according to many investors, hedge funds are viewed as delayed, old investment tools of a period lost to current times.
Orbimed Advisors Takes a Major Stake in Ambit Biosciences Corp (AMBI)
In the smart money’s world, Samuel Isaly’s Orbimed Advisors reported a purchase of some 2.1 million shares of Ambit Biosciences Corp (NASDAQ:AMBI) in a 13D filing with the...
Healthcare Investor Sam Isaly’s Top Stock Picks Include Pfizer
Sam Isaly’s Orbimed Advisors is a large health care fund investing in companies at various stages from venture capital to the public markets.
Why is Orbimed Backing Out of Amarin?
Orbimed Advisors, managed by Samuel Isaly, is a hedge fund with a focus on the healthcare sector.
Hedge Fund News: Paul Tudor Jones, Randy Smith, OrbiMed
The European arm of the Tudor Group, the US hedge fund founded by Paul Tudor Jones II, paid its staff a bumper $62m last year after a profitable 2011, despite the travails of ...
